[go: up one dir, main page]

RU2017126601A - Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras - Google Patents

Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras Download PDF

Info

Publication number
RU2017126601A
RU2017126601A RU2017126601A RU2017126601A RU2017126601A RU 2017126601 A RU2017126601 A RU 2017126601A RU 2017126601 A RU2017126601 A RU 2017126601A RU 2017126601 A RU2017126601 A RU 2017126601A RU 2017126601 A RU2017126601 A RU 2017126601A
Authority
RU
Russia
Prior art keywords
introduction
gst
rnai molecules
tumor
mammal
Prior art date
Application number
RU2017126601A
Other languages
English (en)
Inventor
Венбин ИН
Кендзироу МИНОМИ
Бхарат МАДЖЕТИ
Ли ВАНГ
Цзихуа ЛЮ
Роджер Адами
Original Assignee
Нитто Денко Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нитто Денко Корпорейшн filed Critical Нитто Денко Корпорейшн
Publication of RU2017126601A publication Critical patent/RU2017126601A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Claims (33)

1. Фармацевтическая композиция для лечения или терапии опухоли, ассоциированной с мутацией в гене KRAS или со сверхэкспрессией гена KRAS дикого типа, причем композиция содержит молекулы РНКи и фармацевтически приемлемые вспомогательные вещества, где молекулы РНКи содержат нуклеотидную последовательность, соответствующую последовательности-мишени GST-π.
2. Фармацевтическая композиция по п.1, где молекулы РНКи содержат дуплексную область, содержащую нуклеотидную последовательность, соответствующую последовательности-мишени SEQ ID NO: 287.
3. Фармацевтическая композиция по п.1, где молекулы РНКи содержат антисмысловую цепь, содержащую нуклеотидную последовательность, соответствующую SEQ ID NO: 184, и смысловую цепь, содержащую нуклеотидную последовательность, соответствующую SEQ ID NO: 158.
4. Фармацевтическая композиция по п.1, где молекулы РНКи представляют собой киРНК или кшРНК.
5. Фармацевтическая композиция по п.1, где фармацевтически приемлемые вспомогательные вещества включают одно или более липидных соединений.
6. Фармацевтическая композиция по п.1, где фармацевтически приемлемые вспомогательные вещества включают липидные наночастицы.
7. Фармацевтическая композиция по п.1, где фармацевтически приемлемые вспомогательные вещества включают липидные наночастицы, которые инкапсулируют молекулы РНКи.
8. Способ предотвращения, лечения или ослабления одного или более симптомов злокачественной опухоли, ассоциированной с мутацией KRAS у млекопитающего, нуждающегося в этом, причем способ включает:
идентификацию опухолевой клетки у млекопитающего, причем опухолевая клетка содержит, по меньшей мере, одно из следующего: (i) мутацию гена KRAS и (ii) уровень аберрантной экспрессии белка KRAS; и
введение млекопитающему терапевтически эффективного количества композиции, содержащей одну или более молекул РНКи, которые активны в снижении экспрессии GST-π.
9. Способ по п.8, где млекопитающее представляет собой человека, а GST-π представляет собой человеческий GST-π.
10. Способ по п.8, где молекула РНКи представляет собой киРНК или кшРНК.
11. Способ по п.8, где молекулы РНКи содержат дуплексную область, содержащую нуклеотидную последовательность, соответствующую последовательности-мишени SEQ ID NO: 287.
12. Способ по п.8, где молекулы РНКи содержат антисмысловую цепь, содержащую нуклеотидную последовательность, соответствующую SEQ ID NO: 184, и смысловую цепь, содержащую нуклеотидную последовательность, соответствующую SEQ ID NO: 158.
13. Способ по п.8, где молекула РНКи уменьшает экспрессию GST-π у млекопитающего.
14. Способ по п.8, где введение уменьшает экспрессию GST-π у млекопитающего, по меньшей мере, на 5% в течение, по меньшей мере, 5 дней.
15. Способ по п.8, где введение уменьшает объем злокачественной опухоли у млекопитающего, по меньшей мере, на 5% или, по меньшей мере, на 10% или, по меньшей мере, на 20% или, по меньшей мере, на 30% или, по меньшей мере, на 40% или, по меньшей мере, на 50%.
16. Способ по п.8, где способ уменьшает один или более симптомов злокачественной опухоли или задерживает или прекращает прогрессирование злокачественной опухоли.
17. Способ по п.8, где введение уменьшает рост злокачественных опухолевых клеток у объекта.
18. Способ по п.8, где введение уменьшает рост, по меньшей мере, на 2% или, по меньшей мере, на 5% или, по меньшей мере, на 10% или, по меньшей мере, на 15% или, по меньшей мере, на 20% злокачественных опухолевых клеток у объекта.
19. Способ по п.8, где опухолевые клетки содержат повышенный уровень экспрессии белка KRAS дикого типа по сравнению с таковым в нормальной клетке.
20. Способ по п.8, где опухолевая клетка сверхэкспрессирует РНК или белок GST-π дикого типа.
21. Способ по п.8, где опухолевая клетка содержит мутации в белке KRAS в одном или более из остатков 12, 13 и 61.
22. Способ по п.8, где опухолевая клетка содержит мутации в белке KRAS, и опухоль представляет собой злокачественное новообразование, выбранное из рака легких, рака толстой кишки и рака поджелудочной железы.
23. Способ по п.8, где опухолевая клетка содержит мутации в белке KRAS, и опухоль представляет собой саркому, выбранную из группы, состоящей из аденокарциномы легкого, муцинозной аденомы, протоковой карциномы поджелудочной железы и колоректальной карциномы.
24. Способ по п.8, где злокачественная опухоль представляет собой саркому, выбранную из группы, состоящей из аденокарциномы легкого, муцинозной аденомы, протоковой карциномы поджелудочной железы, колоректальной карциномы, рака молочной железы и фибросаркомы.
25. Способ по п.8, где злокачественная опухоль локализована в анатомической области, выбранной из группы, состоящей из легкого, толстой кишки, поджелудочной железы, желчного пузыря, печени, молочной железы и любой их комбинации.
26. Способ по п.8, где введение осуществляют от 1 до 12 раз в день.
27. Способ по п.8, где введение осуществляют в течение 1, 2, 3, 4, 5, 6 или 7 дней.
28. Способ по п.8, где введение осуществляют в течение 1, 2, 3, 4, 5, 6, 8, 10 или 12 недель.
29. Способ по п.8, где введение представляет собой дозу от 0,01 до 2 мг/кг молекул РНКи, по меньшей мере, один раз в день в течение периода до двенадцати недель.
30. Способ по п.8, где введение обеспечивает среднее AUC (0-конец) от 1 до 1000 мкг*мин/мл и среднее значение Cmax от 0,1 до 50 мкг/мл для молекулы GST-π РНКи.
31. Способ по п.8, где введение представляет собой внутривенную инъекцию, внутрикожную инъекцию, подкожную инъекцию, внутримышечную инъекцию, внутрибрюшинную инъекцию, пероральное введение, местное введение, инфузию или ингаляцию.
RU2017126601A 2014-12-26 2015-12-28 Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras RU2017126601A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014266198 2014-12-26
JP2014-266198 2014-12-26
US201562184204P 2015-06-24 2015-06-24
US62/184,204 2015-06-24
US201562266672P 2015-12-13 2015-12-13
US62/266,672 2015-12-13
PCT/US2015/067559 WO2016106404A2 (en) 2014-12-26 2015-12-28 Methods and compositions for treating malignant tumors associated with kras mutation

Publications (1)

Publication Number Publication Date
RU2017126601A true RU2017126601A (ru) 2019-01-28

Family

ID=56151549

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2017126601A RU2017126601A (ru) 2014-12-26 2015-12-28 Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras
RU2017126598A RU2017126598A (ru) 2014-12-26 2015-12-28 Рнк-агенты для модуляции гена gst-pi
RU2017126610A RU2756253C2 (ru) 2014-12-26 2015-12-28 Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
RU2017126613A RU2719185C2 (ru) 2014-12-26 2015-12-28 Препараты, осуществляющие рнк-интерференцию, для модуляции гена gst-pi

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU2017126598A RU2017126598A (ru) 2014-12-26 2015-12-28 Рнк-агенты для модуляции гена gst-pi
RU2017126610A RU2756253C2 (ru) 2014-12-26 2015-12-28 Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
RU2017126613A RU2719185C2 (ru) 2014-12-26 2015-12-28 Препараты, осуществляющие рнк-интерференцию, для модуляции гена gst-pi

Country Status (10)

Country Link
US (14) US10264976B2 (ru)
EP (9) EP3236974B9 (ru)
JP (10) JP2018512373A (ru)
KR (4) KR102527430B1 (ru)
CN (7) CN107106564A (ru)
AU (4) AU2015369598A1 (ru)
BR (2) BR112017013599A2 (ru)
CA (4) CA2972268A1 (ru)
RU (4) RU2017126601A (ru)
WO (7) WO2016106401A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
ES2789049T3 (es) * 2014-12-26 2020-10-23 Nitto Denko Corp Agentes de interferencia de ARN para modulación génica de GST-pi
US11045488B2 (en) * 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
ES2828717T3 (es) * 2015-06-24 2021-05-27 Nitto Denko Corp Compuestos ionizables y composiciones y usos de los mismos
AU2016371624B2 (en) 2015-12-13 2020-08-27 Nitto Denko Corporation siRNA structures for high activity and reduced off target
CN109477146B (zh) 2016-05-10 2023-09-19 国立大学法人东京医科齿科大学 炎症促进因子表达抑制剂、其有效成分的筛选方法、对该方法有用的表达盒、诊断药和诊断方法
WO2018151840A2 (en) * 2017-02-16 2018-08-23 Nitto Denko Corporation Methods and compositions for treating malignant tumors
US11413243B2 (en) * 2017-11-06 2022-08-16 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
AU2018364001A1 (en) 2017-11-09 2020-06-25 National University Corporation Tokyo Medical And Dental University Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
CN109777798A (zh) * 2017-11-13 2019-05-21 深圳华大生命科学研究院 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用
JP6952594B2 (ja) * 2017-12-15 2021-10-20 洋司郎 新津 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
CN108486011B (zh) * 2018-03-27 2020-05-05 山东大学 一种三联苯化合物、制备方法及其应用
JP7432929B2 (ja) * 2018-05-31 2024-02-19 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途
WO2020009189A1 (ja) * 2018-07-05 2020-01-09 洋司郎 新津 Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤
US20210260095A1 (en) * 2018-08-22 2021-08-26 Nitto Denko Corporation Medicine using hsp47 inhibitor to enhance sensitivity to chemotherapeutic agent
WO2020040186A1 (ja) 2018-08-22 2020-02-27 日東電工株式会社 Ｈｓｐ４７の阻害物質を用いた、がん転移抑制
PT3880212T (pt) 2018-11-16 2024-02-08 Nitto Denko Corp Formulação e métodos de administração de rna de interferência para tumores malignos
CN113038956A (zh) * 2018-12-05 2021-06-25 日东电工株式会社 癌处置用RNAi分子
EP3909588A4 (en) 2019-01-10 2023-01-04 Osaka University IMMUNO-STIMULATING COMPOSITION
CN113677373A (zh) * 2019-03-28 2021-11-19 日东电工株式会社 RNAi分子
JP2019116507A (ja) * 2019-04-25 2019-07-18 有限会社オービット Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法
JP7463410B2 (ja) * 2019-07-02 2024-04-08 アルゴノート アールエヌエー リミテッド アポリポタンパク質ｂアンタゴニスト
US20220267778A1 (en) * 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN112280800B (zh) * 2020-10-19 2022-06-07 上海市东方医院（同济大学附属东方医院） 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用
WO2022144882A2 (en) * 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna target areas for silencing
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
JPWO2023210713A1 (ru) * 2022-04-27 2023-11-02
TW202529777A (zh) * 2023-09-28 2025-08-01 日商日東電工股份有限公司 組合療法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002439A1 (en) 1987-09-21 1989-03-23 Ml Technology Ventures, L.P. Non-nucleotide linking reagents for nucleotide probes
US5204241A (en) 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
DE69431669T2 (de) 1993-09-02 2003-10-23 Ribozyme Pharmaceuticals, Inc. Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
ES2127948T3 (es) 1993-10-27 1999-05-01 Ribozyme Pharm Inc Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido.
EP0831877B1 (en) 1995-06-07 2004-10-27 Telik, Inc. Metabolic effects of certain glutathione analogs
US5968737A (en) 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
JPH10330249A (ja) * 1997-05-30 1998-12-15 Kureha Chem Ind Co Ltd レチノール化合物含有ｈｓｐ４７合成抑制剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999054346A1 (en) 1998-04-16 1999-10-28 Teijin Limited Glutathione derivatives and dosage forms thereof
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2005019453A2 (en) 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US20070083945A1 (en) 2000-03-10 2007-04-12 Byrum Joseph R Nucleic acid molecules and other molecules associated with plants
WO2001088191A1 (en) 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
JP2004508019A (ja) 2000-07-28 2004-03-18 コンピュジェン　インコーポレイテッド トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040219600A1 (en) 2002-12-13 2004-11-04 Williams Robert Wood Method for determining sensitivity to environmental toxins and susceptibility to parkinson's disease
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050142596A1 (en) 2003-11-14 2005-06-30 Krolewski Andrzej S. Methods of diagnosing renal and cardiovascular disease
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
CN101072876B (zh) * 2004-08-26 2012-11-28 恩杰内克分子递送有限公司 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸
US9393315B2 (en) * 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
KR101454286B1 (ko) 2004-12-22 2014-10-27 닛토덴코 가부시키가이샤 섬유화 억제를 위한 약물 담체 및 약물 담체 키트
CA2605068A1 (en) 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
US20070134687A1 (en) * 2005-09-12 2007-06-14 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing cancer
ES2324128A1 (es) * 2005-09-29 2009-07-30 Proyecto De Biomedicina Cima, S.L. Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares.
US20090220956A1 (en) * 2005-10-25 2009-09-03 Dimitry Serge Antoine Nuyten Prediction of Local Recurrence of Breast Cancer
EP2202239A1 (en) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
RU2448974C2 (ru) * 2005-11-01 2012-04-27 Элнилэм Фармасьютикалз, Инк. РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
DE602006005084D1 (de) 2005-11-17 2009-03-19 Childrens Medical Center Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
US7729737B2 (en) 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
US8367628B2 (en) 2005-12-01 2013-02-05 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
EP2584047B1 (en) 2006-05-11 2014-11-19 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
US8067390B2 (en) 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CN101688206B (zh) 2007-07-05 2013-05-15 诺瓦提斯公司 用于治疗病毒感染的dsRNA
EP2193140B1 (en) * 2007-08-27 2016-11-02 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
WO2009033284A1 (en) 2007-09-14 2009-03-19 Mcmaster University Inhibitors of collagen biosynthesis as anti-tumor agents
US8372866B2 (en) * 2008-03-06 2013-02-12 Rottapharm S.P.A. 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain
JP2011528910A (ja) * 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
CN102159247A (zh) * 2008-07-30 2011-08-17 日东电工株式会社 药物载体
EP2496700B1 (en) * 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
KR101692063B1 (ko) 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 hsp47 발현의 조절
US20130053270A1 (en) 2010-02-24 2013-02-28 Bodysync, Inc. Methods for determining gene-nutrient interactions
US20130004494A1 (en) 2010-03-12 2013-01-03 Ellen Heber-Katz Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration
US8372819B2 (en) 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
AU2011249406B2 (en) 2010-05-06 2015-05-14 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
AU2011307259A1 (en) * 2010-09-30 2013-05-02 Nitto Denko Corporation Modulation of TIMP1 and TIMP2 expression
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9011903B2 (en) * 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
DK2718261T3 (en) 2011-06-08 2016-03-29 Nitto Denko Corp Compounds to target drug delivery and promote siRNA activity
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
CN103619355A (zh) * 2011-06-21 2014-03-05 日东电工株式会社 细胞凋亡诱导剂
CN102896619B (zh) * 2011-07-26 2015-04-22 苏州宝时得电动工具有限公司 动力工具及其操作方法
GB2507700A (en) * 2011-08-31 2014-05-07 Alexander A Asea Compositions and methods for treatment of metastatic cancer
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013075140A1 (en) * 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto -recognizing therapeutic rna/dna chimeric nanoparticles (np)
CA2873745A1 (en) * 2012-05-16 2013-11-21 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
US20140134158A1 (en) 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
AU2013270685B2 (en) 2012-06-08 2017-11-30 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
WO2013192364A1 (en) 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Treatments of oxidative stress conditions
CN104684584A (zh) * 2012-07-02 2015-06-03 费卜卢斯坦丁公司 Gpbp-1的抑制及其治疗用途
US9708607B2 (en) * 2012-08-03 2017-07-18 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
CN103695421B (zh) * 2013-12-09 2016-06-15 浙江大学 一种特异抑制p21基因表达的siRNA及其应用
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
CN113559267B (zh) * 2014-12-26 2024-01-12 日东电工株式会社 细胞死亡诱导试剂、细胞增殖抑制试剂及用于治疗由细胞增殖异常导致的疾病的医药组合物
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US10792299B2 (en) * 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
AU2016371624B2 (en) * 2015-12-13 2020-08-27 Nitto Denko Corporation siRNA structures for high activity and reduced off target
JP6899201B2 (ja) 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Also Published As

Publication number Publication date
US20160208254A1 (en) 2016-07-21
AU2015369592A1 (en) 2017-08-10
JP6793649B2 (ja) 2020-12-02
WO2016106401A2 (en) 2016-06-30
JP2018512373A (ja) 2018-05-17
KR102527430B1 (ko) 2023-05-02
AU2015369596A1 (en) 2017-07-27
RU2719185C2 (ru) 2020-04-17
WO2016106404A3 (en) 2016-09-15
AU2015369598A1 (en) 2017-07-27
EP3240796B1 (en) 2020-12-16
WO2016106401A3 (en) 2016-09-15
KR20170100010A (ko) 2017-09-01
US20160186183A1 (en) 2016-06-30
US9695206B2 (en) 2017-07-04
EP3236969A4 (en) 2018-06-13
CN108064155B (zh) 2021-06-08
EP3236973A2 (en) 2017-11-01
USRE49229E1 (en) 2022-10-04
WO2016106403A2 (en) 2016-06-30
US20160208255A1 (en) 2016-07-21
US20160215286A1 (en) 2016-07-28
US9580710B2 (en) 2017-02-28
EP3236945B1 (en) 2021-02-17
AU2015369592B2 (en) 2021-05-06
EP3240796A4 (en) 2018-08-08
EP3236974B9 (en) 2020-08-05
US10264976B2 (en) 2019-04-23
EP3236945A2 (en) 2017-11-01
EP3236974B1 (en) 2020-02-26
JP2025102833A (ja) 2025-07-08
CN107108686A (zh) 2017-08-29
KR20170098929A (ko) 2017-08-30
RU2017126613A3 (ru) 2019-06-05
EP3798308A1 (en) 2021-03-31
US20160186182A1 (en) 2016-06-30
CN108064155A (zh) 2018-05-22
RU2017126610A (ru) 2019-01-28
US20220087531A1 (en) 2022-03-24
EP3236973A4 (en) 2018-09-12
WO2016106405A1 (en) 2016-06-30
CA2972270A1 (en) 2016-06-30
USRE48887E1 (en) 2022-01-11
EP3683309A1 (en) 2020-07-22
CN107106564A (zh) 2017-08-29
EP3236975A4 (en) 2018-09-12
WO2016106402A1 (en) 2016-06-30
EP3236974A4 (en) 2018-06-13
RU2756253C2 (ru) 2021-09-28
JP2018513669A (ja) 2018-05-31
BR112017013599A2 (pt) 2018-03-06
EP3236969A2 (en) 2017-11-01
US10047110B2 (en) 2018-08-14
JP2018512041A (ja) 2018-05-10
BR112017013597B1 (pt) 2024-01-16
US20170298086A1 (en) 2017-10-19
EP3236945A4 (en) 2018-09-12
EP3236975A2 (en) 2017-11-01
US20160208265A1 (en) 2016-07-21
JP7655971B2 (ja) 2025-04-02
JP2023123743A (ja) 2023-09-05
USRE49431E1 (en) 2023-02-28
KR20170093988A (ko) 2017-08-16
WO2016106406A2 (en) 2016-06-30
CN108064153A (zh) 2018-05-22
JP7307137B2 (ja) 2023-07-11
BR112017013597A2 (pt) 2018-03-06
US10023597B2 (en) 2018-07-17
EP3240796A1 (en) 2017-11-08
JP6457645B2 (ja) 2019-01-23
US10047111B2 (en) 2018-08-14
EP3236974A2 (en) 2017-11-01
US10405749B2 (en) 2019-09-10
CN107106592A (zh) 2017-08-29
AU2015369595A1 (en) 2017-07-27
CA2971881C (en) 2023-04-04
WO2016106404A2 (en) 2016-06-30
EP3236976A4 (en) 2018-10-31
JP6730285B2 (ja) 2020-07-29
JP2018512110A (ja) 2018-05-17
JP6865169B2 (ja) 2021-04-28
WO2016106400A3 (en) 2016-09-01
KR20170096199A (ko) 2017-08-23
CA2971881A1 (en) 2016-06-30
CN107106591B (zh) 2020-09-01
US20160208256A1 (en) 2016-07-21
JP2018512060A (ja) 2018-05-10
CN107106591A (zh) 2017-08-29
US9771582B2 (en) 2017-09-26
CN107106592B (zh) 2021-04-27
EP3236976B1 (en) 2021-07-21
WO2016106406A3 (en) 2016-11-03
JP2018513104A (ja) 2018-05-24
JP2018513668A (ja) 2018-05-31
CN107108686B (zh) 2021-07-16
EP3236976A1 (en) 2017-11-01
WO2016106403A3 (en) 2016-08-18
RU2017126598A (ru) 2019-01-28
RU2017126610A3 (ru) 2019-07-17
JP2022036954A (ja) 2022-03-08
CA2972268A1 (en) 2016-06-30
RU2017126613A (ru) 2019-01-28
CN108024961A (zh) 2018-05-11
CA2972265A1 (en) 2016-06-30
US20170218365A1 (en) 2017-08-03
WO2016106400A2 (en) 2016-06-30
US20160376296A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
RU2017126601A (ru) Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras
Liu et al. CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma
CN105407974A (zh) 抗癌组合
ES2956776T3 (es) Composición farmacéutica que comprende miARN-3140 para su uso en el tratamiento del cáncer
CN103656641B (zh) 转录中介体Med23亚基作为靶点用于预防或治疗癌症
ES2908854T3 (es) Método para producir un arenavirus antitumoral así como mutantes de arenavirus
JP2025094223A (ja) Ｓｅｔｄ２を阻害することにより癌を処置する方法
US20110060029A1 (en) Method of treating cancer by modulating epac
JP5891173B2 (ja) がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物
Merhautová et al. Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma.
EP2732044B1 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
US11944636B2 (en) Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen
Liao et al. HIF-1α siRNA and cisplatin in combination suppresstumor growth in a nude mice model of esophageal squamous cell carcinoma
WO2018053270A1 (en) Modified natural killer cells for the treatment of cancer
CN113350527A (zh) 靶向lucat1的反义寡核苷酸及在癌症治疗中的应用
Li et al. PIM1 gene silencing inhibits proliferation and promotes apoptosis of human esophageal cancer cell line Eca-109
WO2016071431A9 (en) A combination for cancer therapy
KR101464360B1 (ko) 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
US20250075210A1 (en) Targeting the ythdf1/arhgef2 axis for cancer treatment
Attar et al. Mechanistic role of pyroptosis in tumor microenvironment and tumor immunotherapy
CN111748625B (zh) miR-515-3p作为食管癌分子标志物的治疗应用
WO2023031996A1 (ja) 癌の浸潤を抑制するための医薬組成物、及び癌の浸潤を抑制する方法
JP2013237623A (ja) 癌治療剤
WO2025226592A1 (en) Cytotoxic synergy of crispr-cas9 with dna damage repair inhibitors
CN110025627A (zh) 一种防治肿瘤的药物及其用途